Lycetamine | CAS#60209-20-3 | antimicrobial

MedKoo Cat#: 596491 | Name: Lycetamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lycetamine is an antimicrobial (Topical).

Chemical Structure

Lycetamine

CAS#60209-20-3

Theoretical Analysis

MedKoo Cat#: 596491

Name: Lycetamine

CAS#: 60209-20-3

Chemical Formula: C22H47N3O

Exact Mass: 369.3719

Molecular Weight: 369.63

Elemental Analysis: C, 71.49; H, 12.82; N, 11.37; O, 4.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lycetamine; P-71; P 71; P71;

IUPAC/Chemical Name

2,6-diamino-N-hexadecylhexanamide

InChi Key

LWEXAPVESMZHFG-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H47N3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-20-25-22(26)21(24)18-15-16-19-23/h21H,2-20,23-24H2,1H3,(H,25,26)

SMILES Code

O=C(NCCCCCCCCCCCCCCCC)C(N)CCCCN

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 369.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Beharry S, Gibbons S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int. 2016 Oct;267:25-34. doi: 10.1016/j.forsciint.2016.08.013. Epub 2016 Aug 11. Review. PubMed PMID: 27552699. 2: Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A. Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues. PLoS One. 2016 Jun 17;11(6):e0157021. doi: 10.1371/journal.pone.0157021. eCollection 2016. PubMed PMID: 27314670; PubMed Central PMCID: PMC4912077. 3: Wink CS, Meyer GM, Meyer MR, Maurer HH. Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett. 2015 Nov 4;238(3):39-44. doi: 10.1016/j.toxlet.2015.08.012. Epub 2015 Aug 11. PubMed PMID: 26276083. 4: Wink CS, Meyer GM, Zapp J, Maurer HH. Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS. Anal Bioanal Chem. 2015 Feb;407(6):1545-57. doi: 10.1007/s00216-014-8414-3. Epub 2015 Jan 11. PubMed PMID: 25577353. 5: Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH. Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. Drug Test Anal. 2014 Oct;6(10):1038-48. doi: 10.1002/dta.1621. Epub 2014 Mar 3. PubMed PMID: 24591097. 6: Carrara M, Zampiron S, Pittarello D, Cima L, Rampa A, Valenti P, Da Re P, Giusti P. Modulation of pharmacological profile of diphenylethane (lefetamine-type) derivatives. Arzneimittelforschung. 1997 Jul;47(7):803-9. PubMed PMID: 9272235. 7: Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 1994 Oct;36(2):139-45. PubMed PMID: 7851281. 8: Massa S, Di Santo R, Mai A, Artico M, Pantaleoni GC, Giorgi R, Coppolino MF. Pyrrylphenylethanones related to cathinone and lefetamine: synthesis and pharmacological activities. Arch Pharm (Weinheim). 1992 Jul;325(7):403-9. PubMed PMID: 1417455. 9: Janiri L, Persico AM, Tempesta E. Dual effects of lephetamine on spontaneous and evoked neuronal firing in the somatosensory cortex of the rat. Neuropharmacology. 1989 Dec;28(12):1405-10. PubMed PMID: 2575715. 10: Mannelli P, Janiri L, De Marinis M, Tempesta E. Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity. Drug Alcohol Depend. 1989 Oct;24(2):95-101. PubMed PMID: 2571492. 11: Massa S, Stefancich G, Artico M, Corelli F, Silvestri R, Pantaleoni GC, Fanini D, Palumbo G, Giorgi R. Synthesis, neuropsychopharmacological effects and analgesic-antiinflammatory activities of pyrrole analogues of lefetamine. Farmaco. 1989 Sep;44(9):763-77. PubMed PMID: 2604832. 12: Janiri L, Mannelli P, Pirrongelli C, Lo Monaco M, Tempesta E. Lephetamine abuse and dependence: clinical effects and withdrawal syndrome. Br J Addict. 1989 Jan;84(1):89-95. PubMed PMID: 2917208. 13: Cagiano R, De Salvia MA, Tattoli M, Lacomba C, Brunello N, Racagni G, Cuomo V. Behavioural and neurochemical changes produced by lefetamine in two inbred strains of mice. Arch Toxicol Suppl. 1989;13:375-7. PubMed PMID: 2774963. 14: Casali R, Nesi MG, Gentili E, Piscitelli P. [Clinical evaluation of analgesia with lefetamine in thoracic surgery]. Minerva Anestesiol. 1987 Jul-Aug;53(7-8):469-72. Italian. PubMed PMID: 3448523. 15: Fontana P, Buonocore P, Agostinis GC. [A new local anesthetic: 0.6% lephetamine. Continuous subarachnoid nerve block in geriatric surgery. Personal method]. Minerva Anestesiol. 1986 Dec;52(12):447-54. Italian. PubMed PMID: 3601114. 16: Fontana P, Buonocore P, Agostinis GC. [Lefetamine 0.6%: continuous subarachnoid nerve block. Our experience through an infusion pump]. Minerva Anestesiol. 1986 Oct;52(10):339-44. Italian. PubMed PMID: 3561819. 17: De Montis MG, Devoto P, Bucarelli A, Tagliamonte A. Opioid activity of lefetamine. Pharmacol Res Commun. 1985 May;17(5):471-8. PubMed PMID: 2994123. 18: Binda GA, Sartini G, Arlandini A, Bianchini A, D'Ambrosio G. [Lephetamine in the treatment of postoperative pain]. Clin Ter. 1984 Dec 31;111(6):545-7. Italian. PubMed PMID: 6525814. 19: Paroli E, Nencini P, Moscucci M. Clinical and experimental evidence of an opiate-like activity of lefetamine. Pharmacol Res Commun. 1984 Sep;16(9):915-22. PubMed PMID: 6095332. 20: Salvatici A, Fontana P, Buonocore P, Cinquegrani A, Vattolo S. [Lefetamine in the control of post-operative pain in abdominal surgery]. Minerva Anestesiol. 1984 Mar;50(3):107-10. Italian. PubMed PMID: 6462477.